Genpharmasec opened higher at ₹1.15, compared with its previous close of ₹1.12. In the last trading session on 12 Nov 2026, the stock traded between ₹1.09 and ₹1.15, with an average traded price of ₹1.11. It showed a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Genpharmasec is now worth
₹ 2,570.00
Resulting in a loss of
₹ 7,430.00 (74.30%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-0.02 (-1.79%)
Day High
₹1.15
Day Low
₹1.09
Day Open
₹1.15
Prev Close
₹1.12
Volume
3,19,332
Value Traded
₹0.04 Cr
1W Return
0.92%
1M Return
10.00%
3M Return
5.77%
6M Return
-12.00%
1Y Return
-23.61%
Market Cap (₹ Cr.)
61
PE Ratio
56.00
PB Ratio
0.92
Dividend Yield
-
ROE
0.85%
ROCE
2.43%
Book Value (₹)
1.22
Face Value (₹)
1.00
EPS (TTM)
0.01
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
0.92%
6 Weeks
-
1 Month
10.00%
3 Months
5.77%
9 Months
-17.91%
Genpharmasec Q2FY27 net profit rises 215% YoY to ₹257 lakh
Standalone net profit rose 215% YoY to ₹257.35 lakh in Q2FY27. Revenue from operations increased 61% YoY to ₹5,083.08 lakh. Board approved disinvestment of stake in Clinigenome India Private Limited. Company Secretary Hardik Makwana resigned effective November 16, 2026.
9 days agoGenpharmasec discloses 34th AGM voting results; all resolutions pass
All five resolutions at Genpharmasec's 34th AGM passed with over 99% majority. Sohan Chaturvedi reappointed as Whole-Time Director for a three-year term. Audited standalone and consolidated financial statements for FY26 adopted. Special resolution for loans and guarantees under Section 185 approved.
1mo agoGenpharmasec Ltd files FY26 annual report with BSE
Genpharmasec Limited filed its FY26 annual report with BSE on September 7, 2026. The submission includes the notice for the 34th Annual General Meeting. The filing complies with SEBI Listing Regulations 34(1) and 36(1)(b). No specific financial results are disclosed in this regulatory letter.
2mo agoGenpharmasec AGM on Sep 29 seeks approval for ₹50 crore loans
Genpharmasec schedules 34th AGM for September 29, 2026, via video conferencing. Agenda includes reappointment of Sohan Chaturvedi as Whole-time Director for three years. Shareholders to approve special resolution for loans/guarantees up to ₹50 crore. Proposed remuneration for Chaturvedi is up to ₹36 lakh per annum. E-voting window opens September 26 and closes September 28, 2026.
2mo agoGenpharmasec promoter Rajesh Sadhwani buys 65 lakh shares
Rajesh Mirchumal Sadhwani acquired 65,00,000 shares in Genpharmasec Ltd via open market purchases. His individual stake increased from 14.09% to 15.26% following the transaction. Combined promoter group holding rose to 32.06% from 30.88%. No shares were encumbered or pledged by the promoters as per the disclosure.
2mo agoGenpharmasec promoter Rajesh Sadhwani buys 50 lakh shares
Rajesh Sadhwani acquired 50,00,000 shares (0.90%) via open market purchase. Individual stake rose from 13.18% to 14.09% following the transaction. Promoter group holding increased to 30.88% from 29.98%. Sneha Sadhwani's holding remained unchanged at 16.80%. No encumbrances or convertible securities involved in the deal.
2mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹354.40 | -1.31% | ₹27,706.09 | 17.80 | +20.22% | |
| ₹288.35 | +0.23% | ₹20,097.73 | 28.10 | -21.29% | |
| ₹440.45 | +2.81% | ₹19,034.47 | 27.80 | +27.43% | |
| ₹1,558.70 | +0.60% | ₹14,659.69 | 20.10 | -30.53% | |
| ₹190.44 | -0.98% | ₹13,597.42 | 20.50 | +23.61% | |
| ₹690.60 | +0.47% | ₹9,590.38 | 96.30 | +12.74% | |
| ₹56.15 | +4.68% | ₹8,422.50 | 26.70 | -15.67% | |
| ₹1,067.70 | -0.39% | ₹7,523.01 | 18.80 | -15.95% | |
| ₹31.01 | -0.55% | ₹7,232.17 | 12.90 | +0.00% | |
| ₹151.25 | +1.34% | ₹6,927.84 | 63.50 | +24.74% | |
| ₹613.95 | -0.96% | ₹6,392.13 | 93.50 | +51.97% | |
| ₹519.90 | -0.21% | ₹5,946.67 | 105.40 | -11.11% |
An investment of ₹10,000 made 5 years ago in Genpharmasec is now worth
₹ 2,570.00
Resulting in a loss of
₹ 7,430.00 (74.30%)
Note: Past profits do not guarantee future returns.
